Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared with Synchronous Axillary Metastases or Recurrent Metastatic Disease

Clinical Breast Cancer

Volumn 15, Issue 5, 2015, Pages 307-312

  Rossi, Sabrina ^a   Basso, Michele ^a   Strippoli, Antonia ^a   Dadduzio, Vincenzo ^a   Cerchiaro, Eleonora ^a   Barile, Rosalba ^a   D'Argento, Ettore ^a   Cassano, Alessandra ^a   Schinzari, Giovanni ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Biomolecular status; Discordance; Lymph nodes; Metastatic disease; Target therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CLINICAL PRACTICE; DISTANT METASTASIS; HUMAN; LYMPH NODE METASTASIS; PRIMARY TUMOR; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVIEW; SYNCHRONOUS AXILLARY LYMPH NODE METASTASIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; LYMPH NODE; METABOLISM; PATHOLOGY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84941314043     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.03.010     Document Type: Review

References (29)

1. S. Heim, M.R. Teixeira, C.U. Dietrich, and N. Pandis Cytogenetic polyclonality in tumors of the breast Cancer Genet Cytogenet 95 1997 16 19
2. T. Kuukasjärvi, R. Karhu, M. Tanner, and et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer Cancer Res 57 1997 1597 1604
3. S.A. Rasbridge, C.E. Gillett, A.M. Seymour, and et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma Br J Cancer 70 1994 335 341
4. E.A. Perez, V.J. Suman, N.E. Davidson, and et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 24 2006 3032 3038
5. NCCN guidelines - version 3.2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed: April 17, 2015.
6. D. Pectasides, A. Gaglia, P. Arapantoni-Dadioti, and et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy Anticancer Res 26 2006 647 653
7. C. Liedtke, K. Broglio, S. Moulder, and et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 2009 1953 1958
8. R. Nishimura, T. Osako, Y. Okumura, R. Tashima, Y. Toyozumi, and N. Arima Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis World J Surg Oncol 9 2011 131
9. J. Liu, H. Deng, W. Jia, and et al. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment J Cancer Res Clin Oncol 138 2012 837
10. N. Niikura, J. Liu, N. Hayashi, and et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors J Clin Oncol 30 2012 593 599
11. J.D. Jensen, A. Knoop, M. Ewertz, and A.V. Laenkholm ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer Breast Cancer Res Treat 132 2012 511 521
12. J. Carlsson, H. Nordgren, J. Sjöström, and et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review Br J Cancer 90 2004 2344 2348
13. M.R. D'Andrea, M.R. Limiti, M. Bari, and et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis Breast Cancer Res Treat 101 2007 279 284
14. S.J. Aitken, J.S. Thomas, S.P. Langdon, D.J. Harrison, and D. Faratian Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Ann Oncol 21 2010 1254 1261
15. L. Strien, M. Leidenius, K. von Smitten, and P. Heikkilä Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells Pathol Res Pract 206 2010 253 258
16. L. Nedergaard, T. Haerslev, and G.K. Jacobsen Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies APMIS 103 1995 20 24
17. V. Guarneri, M.V. Dieci, E. Barbieri, and et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients Ann Oncol 24 2013 2990 2994
18. X. Cui, R. Schiff, G. Arpino, C.K. Osborne, and A.V. Lee Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 2005 7721 7735
19. M.V. Dieci, E. Barbieri, F. Piacentini, and et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis Ann Oncol 24 2013 101 108
20. Z. Varga, R. Caduff, and B. Pestalozzi Stability of the HER2 gene after primary chemotherapy in advanced breast cancer Virchows Arch 446 2005 136 141
21. C. Xiao, Y. Gong, E.Y. Han, A.M. Gonzalez-Angulo, and N. Sneige Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment Ann Oncol 22 2011 1547 1553
22. R.J. Broom, P.A. Tang, C. Simmons, and et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 29 2009 1557 1562
23. F. Cardoso, A. Di Leo, D. Larsimont, and et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes Ann Oncol 12 2001 615 620
24. D. Gancberg, A. Di Leo, F. Cardoso, and et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 2002 1036 1043
25. A.C. Wolff, M.E. Hammond, J.N. Schwartz, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
26. A.C. Wolff, M.E. Hammond, D.G. Hicks, and et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 2013 3997 4013
27. E.A. Mittendorf, Y. Wu, M. Scaltriti, and et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 2009 7381 7388
28. S. Taucher, M. Rudas, R.M. Mader, and et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer Breast Cancer Res Treat 82 2003 207 213
29. A. Vincent-Salomon, M. Jouve, P. Genin, and et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 2002 2169 2173